EDIT - Editas Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.87
+0.14 (+0.71%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close19.73
Open19.78
Bid19.75 x 1400
Ask20.12 x 900
Day's Range19.50 - 20.12
52 Week Range17.80 - 45.02
Volume657,672
Avg. Volume953,774
Market Cap943.738M
Beta (3Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-2.65
Earnings DateFeb 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.71
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results

    CAMBRIDGE, Mass., Feb. 21, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.

  • Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know
    Zacks9 days ago

    Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know

    Editas Medicine (EDIT) closed the most recent trading day at $19.86, moving -0.45% from the previous trading session.

  • Is Moderna a Buy?
    Motley Fool10 days ago

    Is Moderna a Buy?

    The biggest-ever biotech IPO heralds enormous promise for a new class of medicines.

  • Should Sangamo's Failure Make CRISPR Investors Nervous?
    Motley Fool15 days ago

    Should Sangamo's Failure Make CRISPR Investors Nervous?

    The latest gene therapy to flop in a clinical trial pulled CRISPR stocks down with it.

  • Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know
    Zacks15 days ago

    Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Editas Medicine (EDIT) closed at $19.75, marking a +1.65% move from the previous day.

  • GlobeNewswire18 days ago

    Editas Medicine Names David Scadden, M.D., to Board of Directors

    Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden, M.D., to its Board of Directors, effective immediately. Dr. Scadden is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS.

  • Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
    Zacks22 days ago

    Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Editas Medicine (EDIT) closed at $21.60, marking a -0.6% move from the previous day.

  • 3 Biotech Stocks That Are Set for a Breakthrough
    InvestorPlace22 days ago

    3 Biotech Stocks That Are Set for a Breakthrough

    The future of medicine is all about the personalization of medicine. That means doctors will be able to tailor treatments that fit your specific ailments. Not the general ailments of a large population of people. Today, medicine is designed to treat the most common symptoms of a disease. So everyone with that same disease will be given the exact same treatment. But considering we all have different genetic makeups, this method is clearly not ideal. That is where gene editing -- the ability to edit a human's genome -- comes into play. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The term "gene editing" oftentimes has a negative connotation. And given some of the post-apocalyptic movies that have become popular over the years, I can understand why some people are afraid. But genetic editing has so much to offer to the future of medicine. A couple of months ago, a Chinese scientist performed the first gene edit on a human by removing the gene that causes HIV in several newborns. The scientific community was not happy as most believe the science is not far enough along to verify its safety. However, the scientist proved that gene editing does have a place in the healthcare of tomorrow. There are currently more than 10,000 known monogenic diseases that do not have a cure. A monogenic disease is caused by the mutation of one gene. Yes, one single gene. Imagine being able to repair that gene and cure a disease immediately. That's exactly what science is working toward. Sickle cell disease is one of the terrible ailments that falls into this category. Today, those with this disease live with ongoing pain and the knowledge that their life will likely be shortened. But soon, science will be able to cure these people with a single procedure. * 10 Cold Weather Stocks to Heat Up Your Returns Imagine the diseases that could be irradiated through the practice of gene editing. There are many companies working toward this goal, and today I'd like to introduce you to three of the major biotech stocks to buy that focus on gene editing. Source: Shutterstock ### Crispr Therapeutics (CRSP) Crispr Therapeutics AG (NASDAQ:CRSP) is the largest of the Big Three gene-editing biotech stocks, and it has a slight lead in the race. The company made headlines in October when the Food and Drug Administration removed its clinical hold on CTX001, Crispr's gene therapy to treat sickle cell disease. Then, on Jan. 4, the FDA granted the therapy Fast Track status. This is extremely important because it allows for more frequent interaction with the FDA review team as well as a rolling review of the marketing application. Crispr Therapeutics is backed by some powerful pharma partners. Combine that with the promising treatments making headway in the United States and Europe and it is clear that this company is a great place to start investing in this innovative and inspiring trend that should make investors a lot of money. Source: Shutterstock ### Editas Medicine (EDIT) Editas Medicine (NASDAQ:EDIT) falls in the middle of the Big Three gene-editing biotech stocks to buy. It can trace its roots back to the biggest players in the industry, specifically Feng Zhang, whose affiliation with the Broad Institute has given Editas a significant leg up. The Broad Institute owns the patents to use Crispr technology in eukaryotic cells -- more complex cells that have a nucleus where the genetic material is found -- so it puts Editas in an enviable position since it has the exclusive rights to the patents for any genetic target it chooses. * 10 High-Yield Monthly Dividend Stocks This company's promising pipeline and connections make me confident that it is one of the key stocks to buy for investors interested in profiting from gene editing over the long term. Source: Pixelbay (Modified) ### Intellia (NTLA) Intellia Therapeutics (NASDAQ:NTLA) doesn't get the same amount of press as its fellow gene-editing stocks. It is also the smallest of the three, but its upside is just as huge as the other stocks to buy on this list. I say that because Intellia stands out thanks to its proprietary lipid nanoparticle delivery (LNP) technology. This takes drug therapies directly to the genes that need to be edited and does it right there rather than having to extract the gene edit it in the lab. The process has proven to be safer and more effective than the alternatives. Intellia has many irons in the fire as well as collaborations with two successful pharmaceutical companies, and I suspect it could have several therapies in FDA trials in the coming years. The key for gene-editing stocks to buy like NTLA will be to continue their partnerships and show progress, and that's exactly what it is doing. Source: Shutterstock ### Breakthrough Stocks I want to make one final note … gene-editing stocks are what I call buried treasure stocks … you could also call them breakthrough stocks since they're under the biotech frame. That means that the big returns I believe are possible take patience and time. Most investors don't have the long-term outlook that this kind of world-changing technology requires. * The 7 Best Penny Stocks to Buy If that's you, here is my suggestion: Go out and dig a big hole in your backyard. Bury these breakthrough stocks in it, and in 10 years you can dig up your buried treasure. Metaphorically speaking, of course. Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 of the Best Stocks to Buy for a Dovish Federal Reserve * 5 Best Fidelity ETFs for Retirement Savers * 7 Blue-Chip Stocks That Could Lead the Market Higher Compare Brokers The post 3 Biotech Stocks That Are Set for a Breakthrough appeared first on InvestorPlace.

  • How Many Insiders Bought Editas Medicine, Inc. (NASDAQ:EDIT) Shares?
    Simply Wall St.25 days ago

    How Many Insiders Bought Editas Medicine, Inc. (NASDAQ:EDIT) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...

  • Editas Medicine (EDIT) Gains But Lags Market: What You Should Know
    Zacks29 days ago

    Editas Medicine (EDIT) Gains But Lags Market: What You Should Know

    In the latest trading session, Editas Medicine (EDIT) closed at $21.46, marking a +0.61% move from the previous day.

  • GlobeNewswirelast month

    Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Better Buy: CRISPR Therapeutics vs. Editas Medicine
    Motley Foollast month

    Better Buy: CRISPR Therapeutics vs. Editas Medicine

    Which of these gene-editing stocks has the best chance to boost your portfolio?

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Editas Medicine and argenx

    NEW YORK, NY / ACCESSWIRE / January 23, 2019 / U.S. markets declined on Tuesday, breaking a streak of four consecutive days in the green, on growing trade concerns. Stocks were pressured lower on reports ...

  • Editas CEO Resigns — Sending All 3 CRISPR Stocks Into Free Fall
    Investor's Business Dailylast month

    Editas CEO Resigns — Sending All 3 CRISPR Stocks Into Free Fall

    Editas Medicine stock collapsed Tuesday — sending gene-editing stocks Crispr and Intellia also crashing — after Chief Executive Katrine Bosley said she will resign March 1.

  • Why Editas Medicine Is Crashing Today
    Motley Foollast month

    Why Editas Medicine Is Crashing Today

    The CRISPR-focused biotech stock plunged following the surprising resignation of its CEO.

  • MarketWatchlast month

    Editas stock down 21% after announcing CEO departure

    Shares of Editas Medicine, Inc. plummeted 21% on Tuesday after the company announced that Chief Executive and President Katrine Bosley would be stepping down from her role, effective March 2019. Bosley also resigned from the company's board of directors, but will continue in an advisory role until the 2019 to facilitate a smooth transition, the company said. Cynthia Collins, a member of the company's board and former CEO of Human Longevity Inc., will serve as interim chief executive officer while the company searches for a permanent CEO. Bosley joined Editas as CEO in 2014, after working as an entrepreneur in residence at the Broad Institute and helming Avila Therapeutics, which was acquired by Celgene Corporation , as CEO. Shares of Editas Medicine, which develops therapies using the gene-editing technology Crispr, have fallen 9% in the year to date, while the iShares Nasdaq Biotechnology ETF has gained 12.8%. The S&P 500 has gained 5.5%.

  • Editas CEO to step down amid management turnover at gene-editing firm
    American City Business Journalslast month

    Editas CEO to step down amid management turnover at gene-editing firm

    The news comes less than a month after the company's CFO, Andrew Hack, announced that he will also be leaving the company.

  • GlobeNewswirelast month

    Editas Medicine Announces Chief Executive Officer Transition

    Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Katrine Bosley has decided to step down from her role as President and CEO, effective March 1, 2019. Ms. Bosley also resigned from the Company’s Board of Directors.

  • GlobeNewswirelast month

    Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)

    Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology and specificity of EDIT-101, an experimental, CRISPR genome editing medicine being investigated for the treatment of Leber congenital amaurosis 10 (LCA10), a genetically-driven form of blindness. “We are thrilled Nature Medicine published our paper sharing the comprehensive set of pre-clinical data for EDIT-101 and our approach to creating CRISPR-based genome editing medicines,” said Charles Albright, Ph.D., Chief Scientific Officer, Editas Medicine. “The research presented in this important manuscript provided the foundation for our recently accepted Investigational New Drug (IND) application for EDIT-101 to treat LCA10, bringing us closer to the clinic and our goal of realizing the full potential of genome editing.

  • 4 Gene-Editing Technologies That Could Replace CRISPR
    Motley Foollast month

    4 Gene-Editing Technologies That Could Replace CRISPR

    The future of medicine involves the precise engineering of human cells. Turns out, that future may not include that promising CRISPR technique.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Exelixis and Editas Medicine

    NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...